---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-201408"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:12:16.582873+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve reverse split range, authorized share reduction, equity plan amendments via written consent

## Summary
- Ratified amendment to 2018 Equity Plan: shares available increased to 20M, ISO limit to 30M.
- Approved restated plan extending ISO grant period, further raising ISO limit, extending evergreen provision.
- Approved reverse stock split at ratio 1:2 to 1:20, with board discretion for up to one year.
- Approved decrease in authorized common shares from 500M to 100M, effective at board discretion within one year.
- Votes cast by 4,324,964 shares (57.1% of outstanding) on April 28, 2026.

## SEC filing metadata
- accession: 0001193125-26-201408
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000119312526201408/0001193125-26-201408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000119312526201408/d151139d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-201408
- JSON: https://secwatch.observer/filing/0001193125-26-201408.json
- Plain text: https://secwatch.observer/filing/0001193125-26-201408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.